Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

2019 | JOURNAL DOI: 10.1093/ANNONC/MDZ061

1-min quiz | Figure out your research career

See how Impactio can help you with your research career.

Start